

11-07-00
CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"EXPRESS MAIL" MAILING LABEL NUMBER EM474053151US
DATE OF DEPOSIT November 6, 2000
I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE BY
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE
UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE ASSISTANT COMMISSIONER FOR
PATENTS, WASHINGTON, D.C. 20231



U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address Only: Assistant Commissioner
for Patents
Washington, D.C. 20231

Case Docket No. AM100151 01

Roxanne L. Kelly

(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)

Roxanne L. Kelly
(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Sir:

Transmitted herewith for filing is the patent application of

Inventor: Wayne E. Childers et al.

For: Branched Adamantyl and Noradamantyl Aryl- and Aralkylpiperazines
with Serotonin 5-HT1A Activity

This application is a:

- ☒ New Application ☐ CIP Application
- ☐ Divisional Application ☐ Continuation Application
of prior application No. . The entire disclosure of the prior
application, from which a copy of the oath or declaration is supplied, is
considered as being part of the disclosure of the accompanying application
and is hereby incorporated by reference.

Enclosed are:

0 sheets of drawing.

- ☐ Information Disclosure Statement.
- ☐ Preliminary Amendment.
- ☐ Signed statement attached deleting inventor(s) named in the prior application

| CLAIMS AS FILED | | | | |
|---------------------------------|---------------------|---------------------|-------------|------------------------------|
| (1) FOR | (2) NUMBER FILED | (3) NUMBER EXTRA | (4) RATE | (5) BASIC FEE \$710.00 |
| TOTAL CLAIMS | 38 -20 = | 18 | x 18.00 | \$324.00 |
| INDEPENDENT CLAIMS | 4 -3 = | 1 | x 80.00 | \$80.00 |
| MULTIPLE DEPENDENT CLAIMS | 0 | 0 | x 270.00 | 0 |
| TOTAL FILING FEE | | | | \$1114.00 |

- ☒ Please charge American Home Products Corporation Deposit Account No. 01-1425
in the amount of \$ 1114.00 . Two additional copies of this sheet are enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16
and 1.17 which may be required during the entire pendency of this application to
American Home Products Corporation Deposit Account No. 01-1425.

Arnold S. Milowsky
Arnold S. Milowsky
Reg. No. 35,288
November 6, 2000

JC954 U.S. PTO
09/706683
11/06/00

- 1 -

5 **BRANCHED ADAMANTYL AND NORADAMANTYL ARYL- AND**
 ARALKYLPIPERAZINES WITH SEROTONIN 5-HT_{1A} ACTIVITY

 This application claims the benefit of U.S. Provisional Application No.
60/228,820, which was converted from U.S. Patent Application No. 09/439,798, filed
10 November 12, 1999; and U.S. Provisional Application No. Not Yet Known, filed
November 18, 1999, which was converted from U.S. Patent Application No.
09/442,981, pursuant to a petition filed under 37 C.F.R. 1.53(c)(2)(i).

 This invention relates to novel branched adamantyl, noradamantyl aryl and
15 aralkylpiperazines having serotonin 5-HT_{1A} activity. More particularly, the present
invention relates to compounds and methods using them to provide neuroprotection
and prevent, inhibit or limit processes of neurodegeneration in mammals.

Introduction

20 Compounds having selective agonist and partial agonist activity at the 5-HT_{1A}
receptor have established a presence in the marketplace as effective anxiolytic agents
(buspirone, Buspar®, US Patent 3,717,634). Evidence generated over the past 20
years supports the hypothesis that 5-HT_{1A} agonists and partial agonists may find use
25 in the treatment of several diseases such as anxiety, depression, schizophrenia, sexual
dysfunction, cognitive deficits resulting from neurodegenerative diseases like
Alzheimer's Disease, nausea and vomiting, sleep disorders, pain, obesity, pain,
addiction/withdrawal and in the treatment of prostate cancer (for recent reviews, see:
Rasmussen, K. and Rocco, V. P., Recent Progress in Serotonin (5-HT)_{1A} Receptor
30 Modulators, In: *Annual Reports in Medicinal Chemistry, Volume 30*, Bristol, J. A.,
ed., Academic Press, New York, **1995**, pp. 1-9; Schaus, J. M. and Bymaster, F. P.,
Latest Developments in Serotonin Receptor Modulation, In: *Annual Reports in*
Medicinal Chemistry, Volume 33, Bristol, J. A., ed., Academic Press, New York,
1998, pp. 21-30).

35 More recent evidence now indicates that 5-HT_{1A} agonists and partial agonists
act in other disease states and conditions by virtue of their ability to inhibit the release
of glutamate. 5-HT_{1A} agonists and partial agonists may be used to treat conditions

- 2 -

- 5 arising from the dysfunction of the glutamate neurotransmitter system or the aberrant release of glutamate.

Glutamate is the predominant neurotransmitter in the central nervous system and it plays an important role in neuroplasticity. As such, excessive extracellular
10 levels of glutamate have been associated with the pathophysiology of both acute neurodegenerative disorders such as stroke, transient ischemic attack and spinal/brain trauma, as well as chronic neurodegenerative disorders such as epilepsy, Alzheimer's Disease, amyotrophic lateral sclerosis, Huntington's Disease, Parkinson's Disease, AIDS dementia and retinal diseases (Holt, W. F. et al., *Glutamate in Health and*
15 *Disease: The Role of Inhibitors*. In: *Neuroprotection in CNS Diseases*. Bar, P. R. and Beal, M. F., ed., Marcel Dekker, Inc., New York **1997**, pp. 87-119; Engelsen, B. A. et al., *Alterations in Excitatory Amino Acid Transmitters in Human Neurological Disease and Neuropathology*. In: *Neurotoxicity of Excitatory Amino Acids*. Guidotti, A., ed., Raven Press Ltd., New York **1990**, pp. 311 - 332; Ince, P. G. et al., *The Role of Excitotoxicity in Neurological Disease*. *Res. Contemp. Pharmacother.* **1997**, *8*,
20 195 - 212; Meldrum, P. S. *The Glutamate Synapse as a Therapeutical Target: Perspective for the Future*. *Prog. Brain. Res.* **1998**, 441 - 458). Compounds which inhibit or attenuate the release of glutamate represent potential neuroprotective agents for the treatment of ischemia resulting from stroke, transient ischemic attack,
25 brain/spinal trauma and fetal hypoxia (Koroshetz, W. J. and Moskowitz, M. A., *Emerging Treatment for Stroke in Humans*. *Trends in Pharmacol. Sci* **1996**, *17*, 227-233; Dunn, C. D. R. *Stroke: Trends, Treatments and Markets*. *Scrip Reports*, PJB Publications, Richmond **1995**). Ischemia can also result from surgery where the blood flow must be halted for a period of time (e.g., cardiac by-pass surgery) due to
30 the resulting anoxia and hypoglycemia (Arrowsmith, J. E. et al., *Neuroprotection of the Brain During Cardiopulmonary Bypass. A Randomized Trial of Remacemide During Coronary Artery Bypass in 171 Patients*, *Stroke* **1998**, *29*, 2357-2362, and references cited within).

35 Serotonin 5-HT_{1A} receptors are located in brain areas which are highly sensitive to ischemia, such as the hippocampus and cerebral cortex. Activation of this receptor subtype results in neuronal hyperpolarization and a concomitant inhibition of neuronal activity (DeVry, J. *5-HT_{1A} Receptor Agonists: Recent Developments and*

- 3 -

5 Controversial Issues. *Psychopharmacology* **1995**, 121, 1 - 26). Moreover, it has
been demonstrated that 5-HT_{1A} receptor agonists and partial agonists are able to
attenuate glutamate release, most likely through activation of 5-HT_{1A} receptors
located on glutamatergic terminals (Matsuyama, S. et al., Regulation of Glutamate
Release via NMDA and 5-HT_{1A} Receptors in Guinea Pig Dentate Gyrus. *Brain Res.*
10 **1996**, 728, 175-180) and that a number of 5-HT_{1A} agonists and partial agonists exert
neuroprotective properties *in vivo* (DeVry, J. et al., BAY x 3702, *Drugs of the Future*
1997, 22, 341-349, and references cited within).


15 Therefore, in addition to its well established potential therapeutic applications,
compounds which possesses 5-HT_{1A} agonist or partial agonist activity may be used
as neuroprotective agents as well as a means for treating psychosis.

Preclinical models, neurochemical hypotheses and brain localization have
predicted a number of potential therapeutic targets for serotonin 5-HT_{1A} antagonists
20 as well. These targets include the cognitive deficits observed in Alzheimer's Disease,
anxiety, depression, schizophrenia and urinary incontinence (for a review see
Schechter, L. E. and Kelly, M. G., An Overview of 5-HT_{1A} Receptor Antagonists:
Historical Perspective and Therapeutic Targets, in *Serotonin - Current Drugs ID*
Research Alert **1997**, 2, 299-309).

25

Description of the Invention

In accordance with this invention, there is provided a set of novel compounds,
including their enantiomers, which have activity as serotonin 5-HT_{1A} agonists,
30 partial agonists and antagonists. Compounds of the present invention are described
by the formula I:



- 4 -

5 wherein:

X is selected from $-\text{CH}_2-$ or a chemical bond;

Y is selected from $-(\text{CH}_2)_m-$ or $-(\text{CH}_2)-\text{O}-(\text{CH}_2)-$;

10

m is selected from the integer 0 or 1;

n is selected from the integer 0 or 1;

15

R₁ and R₂ are independently selected from the group consisting of aryl or heteroaryl of from 5 – 10 atoms optionally substituted with F, Cl, Br, I, -OH, -NH₂, -CO₂H, -CO₂-C₁-C₆ alkyl, -CN, -NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆perhaloalkyl, OR₃, or C₁-C₆ perhaloalkoxy;

20

R₃ is selected from the group consisting of H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₆-C₁₀ aryl, mono or bicyclic heteroaryl, C₇-C₁₄ aralkyl, and mono or bicyclic heteroaralkyl, where the aryl or heteroaryl group is optionally substituted with one to three substituents independently selected from the group consisting of F, Cl, Br, I, CN, -NH₂, -NO₂, -OH, alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆perhaloalkyl, C₁-C₆ alkoxy, and C₁-C₆ perhaloalkoxy;

25

the optical isomers;

and the pharmaceutically acceptable salts thereof.

30

The term C₆-C₁₀ aryl includes phenyl and naphthyl. Monocyclic heteroaryl means a 5-6 membered heteroaryl group having from 1-3 heteroatoms selected independently from N, O, and S, such as pyridine, pyrrole, thiophene, furan, imidazole, oxazole, pyrimidine, pyridazine, pyrazine, thiazole and oxathiazole.


35

Bicyclic heteroaryl includes phenyl fused to a monocyclic 5-6 membered heteroaryl group or a 5-6 membered heteroaryl group fused to another 5-6 membered heteroaryl group, including, but not limited to indole, quinoline, isoquinoline, benzofuran, benzodioxan, benzothiophene, benzimidazole, naphthyridine, and imidazopyridine.

- 5 -

- 5 The term C_7-C_{14} aralkyl means a C_1-C_4 alkyl group having a phenyl or naphthyl group as a substituent, and the term heteroaralkyl means a C_1-C_4 alkyl group having a mono or bicyclic heteroaryl group as defined above as a substituent.

Among the preferred compounds of this invention are those of the formula:



Y is selected from $-(CH_2)_m-$ or $-(CH_2)-O-(CH_2)-$;

m is selected from the integer 0 or 1;

n is selected from the integer 0 or 1;

R_1 is phenyl optionally substituted with F, Cl, Br, I, -OH, -NH₂, -CO₂H, -CO₂-
 C_1-C_6 alkyl, -CN, -NO₂, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-
 20 C_6 perhaloalkyl or C_1-C_6 perhaloalkoxy;

R_2 is selected from phenyl, naphthyl, piperazinyl, pyridine, thiophene, furan,
 imidazole, oxazole, pyrrole, pyrimidine, pyridazine, pyrazine, thiazole or oxathiazole;


25 the optical isomers;

and the pharmaceutically acceptable salts thereof.

Further preferred compounds of this invention are those of the formula:

30

- 6 -



5

Y is selected from -CH₂-;

m is selected from the integer 0 or 1;

n is selected from the integer 0 or 1;

10

R₁ is phenyl optionally substituted with F, Cl, Br, I, -OH, -NH₂, -CO₂H, -CO₂-C₁-C₆ alkyl, -CN, -NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perhaloalkyl or C₁-C₆ perhaloalkoxy;

R₂ is phenyl or pyrimidinyl;

the optical isomers or a pharmaceutically acceptable salt thereof.

15

Optical isomers of the invention compounds can be selectively synthesized or separated using conventional procedures known to those skilled in the art of organic synthesis.

20

The pharmaceutically acceptable salts of the invention compounds include the conventional acid addition salts which are formed from an invention compound and a pharmaceutically acceptable organic or inorganic acid. The acid addition salts include, but is not limited to, the acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, dodecylsulfate, ethanesulfonate, fumarate, glycerophosphate, phosphate, hemisulfate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, nicotinate, oxalate, pamoate, pectinate, pivalate, propionate, succinate, tartrate, and tosylate. Also the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, dialkyl sulfates, long chain halides such as lauryl bromide, aralkyl halides like benzyl and phenethyl bromides.

25

30

Methods of treatment of this invention include those glutamate-mediated maladies wherein inhibition of glutamate release is desirable. These methods may

- 7 -

5 be characterized as methods for inhibiting or limiting neuronal glutamate release in a mammal, the method comprising administering to the mammal, preferably to a human patient, a pharmaceutically effective amount of a compound of this invention, or a pharmaceutically effective salt thereof.

10 As such, these compounds may be useful in the treatment of several diseases such as anxiety, depression, schizophrenia, sexual dysfunction, cognitive deficits resulting from neurodegenerative diseases including Alzheimer's Disease, nausea and vomiting, epilepsy, sleep disorders, obesity, pain, addiction/withdrawal, urinary incontinence, prostate cancer, and ischemia resulting from acute stroke, transient
15 ischemic attack, head and spinal trauma, fetal hypoxia, neuronal hypoxia, cardiac surgery or any other surgical technique which requires halting the blood flow for a period of time.

The methods of this invention are also useful in inhibiting or limiting the
20 chronic neurodegenerative actions associated with Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, epilepsy, amyotrophic lateral sclerosis, AIDS dementia as well as retinal diseases. Therefore, this invention also comprises methods of treatment for each of these maladies, the methods comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of this
25 invention, or a pharmaceutically acceptable salt thereof.

The compounds of this invention may also be used in the mediation or inhibition of glutamate activity associated with the maladies known as chronic, neuropathic or persistent pain, including its actions in fibromyalgia, postherpetic
30 neuralgia, reflex sympathetic dystrophy, diabetic peripheral neuropathy, etc.

Of particular interest is methods of using the compounds of this invention to treat, prevent, limit, inhibit, delay or alleviate neurodegeneration in a mammal, the methods comprising administering to a mammal in need thereof a pharmaceutically
35 effective amount of a compound of this invention, or a pharmaceutically acceptable salt thereof. These methods include those in which the neurodegenerative disease or disorder is acute or chronic. Included are those instances in which the neurodegeneration results from stroke, including thromboembolic stroke, focal


- 8 -

5 ischemia, global ischemia and tranient ischemic attack. Also included are those neurodegenerative disorders such as ischemia resulting from a surgical technique involving prolonged halt of blood flow to the brain, head or spinal trauma, or hypoxia, including fetal hypoxia.

10 For their ability to inhibit, prevent or limit further neural degradation in the hypoxic and ischemic events of the maladies described above, the methods of treatment of this invention may also be characterized as methods for providing or inducing neuroprotection in a mammal, as their activity reduces or inhibits the glutamate-mediated or glutamate-related degeneration which would naturally occur.

15 The compound of formula I can be prepared by conventional chemical methods which are well known to those skilled in the art of chemistry using chemicals that are either commercially available or readily prepared following standard literature procedures. For example, the compounds may be synthesized in
20 four steps (Scheme 1) starting from the appropriate phenylalanine, phenylglycine or heteroaryl-substituted alanine or heteroaryl-substituted glycine which has been protected on the nitrogen atom with a suitable protecting group such as the t-butoxycarbonyl group (BOC). This material is coupled to the appropriately substituted arylpiperazine or aralkyl piperazine using a suitable coupling catalyst,
25 such as dicyclohexylcarbodiimide (DCC) to afford compound 1. Removal of the BOC group under acidic conditions followed by reduction using an appropriate reducing agent such as lithium aluminum hydride or a borane complex leads to the penultimate intermediate 3. Subsequent acylation of 3 with a suitable acylating agent such as adamantane-1-carboxylic acid chloride or noradamantyl-3-carboxylic acid
30 chloride gives compounds of formula I, which are isolated as acceptable salts.

- 9 -




Scheme 1

In cases where the R_2 grouping is not compatible with the reductive conditions required for the conversion of intermediate **2** to intermediate **3**, it may be introduced after the reduction of the amide by initially protecting the NH group of the piperazine with a benzyl moiety (Scheme 2). This benzyl group can then be removed under catalytic hydrogenation conditions and the R_2 group incorporated into the molecule to give the final products.

The starting materials required for the synthesis of the compounds of formula I are either commercially available or readily obtained using conventional methods described in the literature. The preparative method described above is not meant to be restrictive but only illustrative since other methods of preparing the compounds of formula I may be obvious to those skilled in the art of chemistry. For example, while numerous, N-protected amino acids are commercially available, the protecting group may alternatively be introduced onto an amino acid using conventional methods which are well described in the literature. Other protecting groups such as carbobenzyloxy (CBZ) may be employed to protect the nitrogen grouping in the first step of the synthesis and many other coupling catalysts may serve to effect the reaction. Exact reagents required to de-protect the amine group of intermediate **1** once the coupling has been effected will depend on the protecting group used and the

- 10 -

5 substituents present in the molecule. Other reducing agents besides LAH or borane may serve to accomplish the reduction of intermediate **2**. Finally, the introduction of the acyl-adamantyl or acyl-noradamantyl group may be accomplished according to the general method described in Scheme 1 using one of many possible acylating derivatives, which include but are not limited to acid halides (e.g., acid chloride),
 10 anhydrides and activated esters and amides or through the use of adamantyl- or noradamantyl carboxylic acid and an appropriate coupling catalyst.



Scheme 2

15

Since numerous chirally pure amino acids and protected amino acids are either commercially available or known in the literature, the pure optical isomers of the compounds of formula I may be obtained stereospecifically by beginning the
 20 synthesis with chirally pure starting materials. Alternatively, the optical isomers of the compounds of formula I may be obtained by conventional separation methods which are well known to those skilled in the art of synthetic chemistry. These

- 11 -

5 methods include but are not restricted to crystallization of a mixture of diastereomeric salts, enzymatic resolution, chromatography of one of the intermediates or the final product on a chiral column, or formation and separation of a diastereomeric mixture followed by conversion back to the chirally pure material.

10 The following examples are included for illustrative purposes only and are not intended to be considered as limiting to this disclosure in any way.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206

5

Example 1

(R)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate

10

(R)-Phenylalanine-N-[4-(phenylmethyl)-1-piperizinyl]carboxamide

Dihydrochloride. D-Phenylalanine-N-t-butoxycarboxamide (13.25 g, 50 mmol) and 1-benzylpiperazine (8.8 g, 50 mmol) were dissolved in 125 mL of dry dichloromethane and cooled in an ice bath. The stirred mixture was then treated with a solution of diethylcyanophosphonate (8.97 g, 55 mmol) in 50 mL of dry dichloromethane over a period of 45 minutes. A solution of N-methylmorpholine (5.55 g, 55 mmol) in 50 mL of dry dichloromethane was then added over a period of one hour. The resulting reaction mixture was stirred overnight, during which time it came up to room temperature. The solution was then washed with 100 mL of 10% aqueous potassium carbonate, dried over anhydrous sodium sulfate, and concentrated on a rotary evaporator to yield 26 g of the crude intermediate BOC-(R)-phenylalanine-N-(4-benzyl-1-piperazinyl)carboxamide. This oil was dissolved in 200 mL of dichloromethane and treated with a 4.6 N solution of HCl in ethyl acetate (350 mL). After stirring at room temperature for one hour (at which time CO₂ evolution ceased), 250 mL of dry diethyl ether was added. The desired dihydrochloride salt of (R)-phenylalanine-N-[(4-phenylmethyl)-1-piperazinyl]-carboxamide (18.9 g, 95%) precipitated and was isolate by filtration, washed with diethyl ether, and dried in vacuo: mp = 140 - 150°C; [α -D]_D²⁵ = -3.7° (c = 1, MeOH); MS *m/z* = 323 (M⁺).

30

(R)-[1-(Phenylmethyl)-2-[(4-phenylmethyl)-1-piperazinyl]ethyl]amine. A

solution of (R)-phenylalanine-N-[(4-phenylmethyl)-1-piperazinyl]carboxamide dihydrochloride (18.8 g, 47.4 mmol) in 230 mL of 1 M borane/tetrahydrofuran was refluxed with stirring for four hours under a nitrogen atmosphere. The resulting mixture was cooled in an ice bath and quenched by slow addition of 150 mL of 2N aqueous HCl. The resulting mixture was then refluxed with stirring overnight. The tetrahydrofuran was removed under reduced pressure. The filtrate was washed with five 50 mL portions of dichloromethane and then made strongly basic with 50% aqueous sodium hydroxide solution. The resulting alkaline mixture was then

35

- 13 -

5 extracted with three 100 mL portions of dichloromethane. The combined organic layers were dried over anhydrous sodium sulfate and concentrated on a rotary evaporator to yield the desired (R)-[1-(phenylmethyl)-2-[(4-phenylmethyl)-1-piperazinyl]ethyl]amine (17.1 g, 95%) as a yellow oil which was used without further purification. A sample of this oil was converted to the trihydrochloride sesquihydrate salt with ethyl acetate/HCl for characterization: m.p. = 183 – 185 C; $[\alpha\text{-D}]^{25} = -27.7$ (c= 1, MeOH); MS $m/z = 309$ (M^+).

Analysis for $C_{20}H_{25}N_3O \cdot 3 HCl \cdot 1\frac{1}{2} H_2O$

Calculated: C: 53.83; H: 7.40; N: 9.42

15 Found: C: 54.22; H: 7.11; N: 9.24.

(R)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]-ethyl]tricyclo-[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate.

20 To an ice-cooled solution of 1-adamantanecarboxylic acid (5.1 g, 50 mmol) and (R)-[1-(phenylmethyl)-2-[(4-phenylmethyl)-1-piperazinyl]ethyl]amine (9.6 g, 25 mmol) in 60 mL of dry dichloromethane was added, with stirring, diethylcyanophosphonate (4.1 g, 25 mmol) over a period of thirty minutes. Upon completed addition, N-methylmorpholine (2.53 g, 25 mmol) was added and the resulting mixture was stirred overnight during which time it came up to room temperature. The reaction mixture
25 was then washed with 100 mL of 10% aqueous potassium carbonate solution followed by 100 mL of water. The resulting organic layer was dried over anhydrous sodium sulfate and concentrated on a rotary evaporator. The desired product was isolated by chromatography on silica gel using a gradient of ethyl acetate and hexane and then converted to its dihydrochloride dihydrate salt (6.30 g, 44%) with HCl/ethyl
30 acetate: mp = 261-263°C; $[\alpha\text{-D}]^{25} = -12.5^\circ$ (c=1, MeOH); CIMS $m/z = 472$ (MH^+).

Analysis for $C_{31}H_{41}N_3O \cdot 2 HCl \cdot 2 H_2O$

Calculated: C: 64.12; H: 8.16; N: 7.24

Found: C: 63.92; H: 8.30; N: 6.90.

35

- 14 -

5 **Example 2**

(S)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate

10

Beginning with L-phenylalanine-N-t-butoxycarboxamide, (S)-N-[1-(phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide was prepared using a synthetic sequence identical to that described for the synthesis of Example 1. It was isolated as its dihydrochloride dihydrate salt in 9% overall yield: mp 263 - 266°C; $[\alpha]_D^{25} = +11.3$ (c=1.03, MeOH); CIMS $m/z = 472$ (MH⁺).

15

Analysis for C₃₁H₄₁N₃O • 2 HCl • 2 H₂O

Calculated: C: 64.12; H: 8.16; N: 7.24

20

Found: C: 64.13; H: 7.86; N: 7.27.

Example 3

25

(R)-N-[1-(Phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide Hemihydrate

30

35

The compound of Example 1 (4.5 g, 7.84 mmol) was hydrogenated over 10% Pd/C (1 g) in 200 mL of ethanol on a Parr shaker at a pressure of 36 psi overnight. The catalyst was removed by filtration through Celite and the mixture concentrated on a rotary evaporator to yield the crude (R)-N-[1-(phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide (2.8 g) as an oil. This oil was dissolved in 50 mL of dry dimethylformamide. To the stirred solution was added 2-chloropyrimidine (1.05 g, 9.2 mmol), anhydrous potassium carbonate (12.4 g, 90 mmol), and triethylamine (1 mL), and the resulting mixture was heated at 70°C overnight. The DMF was removed on a rotary evaporator and the residue was triturated with water. The resulting precipitate was washed with water, air-dried, and recrystallized from 50% aqueous methanol to yield the desired compound as a hemihydrate: mp 172-175°C;

- 15 -

5

$[\alpha\text{-D}]^{25} = -9.7^\circ$ ($c=1.07$, MeOH); CIMS $m/z = 460$ (MH^+).

Analysis for $\text{C}_{28}\text{H}_{35}\text{N}_5\text{O} \cdot \frac{1}{2} \text{H}_2\text{O}$

Calculated: C: 71.76; H: 8.17; N: 14.95

Found: C: 71.90; H: 8.02; N: 14.82.

10

Example 4

(S)-N-[1-(Phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide

15

Beginning with the compound of Example 2, (S)-N-[1-(phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide was prepared using a synthetic sequence identical to that described for the synthesis of Example 3. It was isolated in 78% overall yield: mp 172 - 175°C; $[\alpha\text{-D}]^{25} = +7.20$ ($c=1.03$, MeOH); CIMS $m/z = 460$ (MH^+).

20

Analysis for $\text{C}_{28}\text{H}_{37}\text{N}_5\text{O}$

Calculated: C: 73.17; H: 8.11; N: 15.24

Found: C: 72.87; H: 7.90; N: 15.00.

25

Example 5

(R)-N-[1-((Phenylmethoxy)methyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo-[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate

30

Beginning with D-O-benzylserine-N-t-butoxycarboxamide, (R)-N-[1-((phenylmethoxy)-methyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-tricyclo-[3.3.1.1^{3,7}]-decane-1-carboxamide was prepared using a synthetic sequence identical to that described for the synthesis of Example 1. It was converted to its dihydrochloride dihydrate salt with ethyl acetate/HCl and isolated in 5% overall yield: mp 140 - 142°C; $[\alpha\text{-D}]^{25} = +19.0$ ($c=0.98$, MeOH); CIMS $m/z = 502$ (MH^+).

35

- 16 -

5 Analysis for $C_{32}H_{43}N_3O_2 \cdot 2 HCl \cdot 2 H_2O$
 Calculated: C: 62.94; H: 8.08; N: 6.88
 Found: C: 62.74; H: 8.07; N: 6.86.

Example 6

10 **(R)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hemihydrate**

15 **(R)-[1-(Phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxo-ethyl]-carbamic acid tert-butyl ester.** To a 0°C solution of D-phenylalanine-N-t-butoxy-carboxamide (10.0 g, 37.7 mmol), 1-hydroxybenzotriazole (8.66 g, 64.1 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (7.20 g, 37.7 mmol) in dry dimethylformamide (50 mL) under a nitrogen atmosphere, was added 1-(2-methoxyphenyl)-piperazine (9.50 g, 41.5 mmol), followed by N-methylmorpholine (7.62 g, 75.4 mmol). The resulting mixture was stirred under nitrogen overnight, during which time it came up to room temperature. The reaction mixture was diluted with ethyl acetate and then washed with 0.1 N aqueous HCl, saturated aqueous sodium bicarbonate and saturated sodium chloride solution. The combined organic layers dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield the desired product (16.57 g, 99% yield) as a yellow oil which was pure enough to use without further purification: $[\alpha-D]^{25} = -9.0$ (c=1, MeOH); MS $m/z = 439$ (M^+).

25 Analysis for $C_{25}H_{33}N_3O_4$
30 Calculated: C: 68.31; H: 7.57; N: 9.56
 Found: C: 68.09; H: 7.17; N: 9.46.

35 **(R)-1-(Phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethylamine.** A solution of (R)-[1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxo-ethyl]-carbamic acid tert-butyl ester (16.37 g, 37.3 mmol) in a mixture of dioxane (150 mL)/4N aqueous HCl (150 mL) was stirred at room temperature for 6 hours. The reaction mixture was then concentrated under reduced pressure and the aqueous mixture was extracted with diethyl ether. The combined

- 17 -

5 organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield the desired (R)-[1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxoethyl]amine hydrochloride (14.0 g, 100% yield) as an off-white solid, which was used in the next step without further purification.

10 To a solution of (R)-[1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxo-ethyl]amine hydrochloride (14 g, 37.3 mmol) and triethylamine (7.53 g, 74.6 mmol) in anhydrous tetrahydrofuran (150 mL) under a nitrogen atmosphere was added, dropwise, a 1M solution of borane in tetrahydrofuran (131 mL, 130.6 mmol). The resulting mixture was stirred at reflux for three hours, then
15 allowed to stir at room temperature overnight. The resulting mixture was treated with 2N aqueous HCl (300 mL) for two hours and the layers were separated. The acidic aqueous layer was washed with ethyl acetate, made basic with 50% aqueous sodium hydroxide, and extracted with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium chloride solution, dried over anhydrous
20 sodium sulfate and concentrated under reduced pressure. The desired product (11.0 g, 91.0% yield) was isolated as an off-white solid: m.p. = 95 – 97°C;

[α -D]²⁵ = -36.7 (c=1, MeOH); FAB MS m/z = 326 (MH⁺).

Analysis for C₂₀H₂₇N₃O

25 Calculated: C: 73.80; H: 8.37; N: 12.77

Found: C: 73.15; H: 8.34; N: 12.68

(R)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hemihydrate. To a solution of
30 (R)-1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]amine (0.25 g, 0.77 mmol) and triethylamine (0.16 g, 1.54 mmol) in anhydrous dichloromethane (15 mL) under a nitrogen atmosphere at 0 °C was added a solution of 1-adamantane-carboxylic acid chloride (0.17 g, 0.84 mmol) in dichloromethane (5 mL). The resulting solution was allowed to stir overnight under nitrogen, during which time it
35 came up to room temperature. The reaction mixture was then concentrated under reduced pressure, diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The desired product was purified by flash chromatography on silica gel

- 18 -

- 5 (ethyl acetate/hexane) and converted to its hemifumarate hemihydrate salt with fumaric acid/ethanol to yield 0.30 g (71% yield) as a white solid: m.p. = 153 – 155°C; $[\alpha\text{-D}]^{25} = -9.0$ (c=1, MeOH); MS m/z = 487 (M+).

Analysis for $\text{C}_{31}\text{H}_{41}\text{N}_3\text{O}_2 \cdot \frac{1}{2} \text{C}_4\text{O}_4 \cdot \frac{1}{2} \text{H}_2\text{O}$

- 10 Calculated: C: 71.45; H: 8.00; N: 7.57
Found: C: 71.26; H: 8.05; N: 7.42.

Example 7

- 15 **(S)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hydrate**

- This compound was prepared using an identical synthetic sequence to that described for Example 6 starting with L-phenylalanine-N-t-butoxy-carboxamide. The overall yield was 61% and the compound (an off-white solid) was isolated as the hemifumarate hydrate salt: m.p. = 157 – 159°C; $[\alpha\text{-D}]^{25} = +9.5$ (c=1, MeOH); FAB MS m/z = 488 (MH⁺).

Analysis for $\text{C}_{31}\text{H}_{41}\text{N}_3\text{O}_2 \cdot \frac{1}{2} \text{C}_4\text{O}_4 \cdot \text{H}_2\text{O}$

- 25 Calculated: C: 70.31; H: 8.05; N: 7.45
Found: C: 70.21; H: 8.04; N: 7.11.

In Vitro Data

- 30 Affinity for the serotonin 5-HT_{1A} receptor was established by assaying the test compound's ability to displace [³H]-8-OH-DPAT from its binding site on the receptor complex in rat hippocampal membrane homogenates according to the method described in US Patent 5,482,940. The compounds of this invention displayed high affinity for the 5-HT_{1A} receptor, as exemplified by the data given in
35 Table 1.

Some of the compounds of this invention displayed serotonin 5-HT_{1A} agonist activity, as measured by the test compounds's ability to stimulate the binding of

- 19 -

- 5 [35S]-GTP γ S to the 5-HT_{1A} receptor-G protein complex in CHO cells stably transfected with the human 5-HT_{1A} receptor following a variation of the procedure described by Lazerino and Birdsall (*Br. J. Pharmacol.*, **109**, 1120 (1993)). Data are given in Table 1. Data are presented as the percent of

10

Table 1

| Example | 5-HT _{1A} Affinity (IC ₅₀) | 5-HT _{1A} Agonist Activity (GTP γ S) | | 5-HT _{1A} Antagonist Activity (GTP γ S) | |
|---------|---|---|------------------|--|------------------|
| | | % Agonist Activity | EC ₅₀ | % Antagonist Activity | EC ₅₀ |
| 1 | 2.3 nM | | | 100% | 36 nM |
| 2 | 0.70 nM | 51% | 21 nM | | |
| 3 | 0.43 nM | 100% | 2.0 nM | | |
| 4 | 1.0 nM | 99% | 2.4 nM | | |
| 5 | 62 nM | 49% | 77 nM | | |
| 6 | 0.21 nM | 76% | 2.0 nM | | |
| 7 | 0.70 nM | 85% | 2.0 nM | | |

- agonist activity observed relative to the effect obtained with the 5-HT_{1A} full agonist 8-OH-DPAT and the corresponding EC₅₀ value. As can be seen from Table 1, the
15 compounds of this invention are potent 5-HT_{1A} ligands which display agonist and partial agonist activity in the GTP γ S assay.

- Some of the compounds of this invention displayed serotonin 5-HT_{1A} antagonist activity, as measured by the test compound's ability to block the
20 stimulation of the binding of [35S]-GTP S to the 5-HT_{1A} receptor-G protein complex induced by the 5-HT_{1A} full agonist 8-OH-DPAT in CHO cells stably transfected with the human 5-HT_{1A} receptor following a variation of the procedure described by Lazerino and Birdsall (*Br. J. Pharmacol.*, 109, 1120 (1993)). Data are
25 given in Table 1. As can be seen from Table 1, some of the compounds of this invention are potent 5-HT_{1A} ligands which display antagonist activity in the GTP S assay.

- 20 -

5 These activities make the compounds of this invention useful for the treatment
of several diseases such as anxiety, depression, schizophrenia, sexual dysfunction,
cognitive deficits resulting from neurodegenerative diseases like Alzheimer's
Disease, nausea and vomiting, epilepsy, sleep disorders, obesity, pain,
addiction/withdrawal, urinary incontinence, prostate cancer, and ischemia resulting
10 from acute stroke, transient ischemic attack, head and spinal trauma, fetal hypoxia,
cardiac surgery or any other surgical technique which requires halting the blood flow
for a period of time, and chronic neurodegenerative diseases such as Alzheimer's
Disease, Huntington's Disease, Parkinson's Disease, amyotrophic lateral sclerosis,
AIDS dementia as well as retinal diseases.

15 **Pharmaceutical Composition**

 This invention also comprises pharmaceutical compositions comprising
pharmaceutically effective amounts of one or more compounds of this invention, or a
20 pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable
carriers or excipients. The pharmaceutically effective amount of these compounds
will be understood to be an amount which provides an effective degree of
neuroprotection or treats, inhibits or limits the neurodegeneration in question. In
humans, a daily dosage of from about 100 mg to about 1,500 mg per day may be
25 administered, preferably between about 300 mg and about 1,200 mg per day, more
preferably between about 500 mg and 1,000 mg per day. These dosages may be
administered in a single administration or divided into multiple doses for sequential
administration.

30 The compounds of the present invention may be administered orally or
parentally, neat or in combination with conventional pharmaceutical carriers.
Applicable solid carriers can include one or more substances which may also act as
flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants,
compression aids, binders, tablet-disintegrating agents or encapsulating materials. In
35 powders, the carrier is a finely divided solid which is in admixture with the finely
divided active ingredient. In tablets, the active ingredient is mixed with a carrier
having the necessary compression properties in suitable proportions and compacted in
the shape and size desired. The powders and tablets may contain up to 99% of the
active ingredient. Suitable solid carriers include, for example, calcium phosphate,

- 21 -

5 magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl
cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes
and ion exchange resins. Liquid carriers may be used in preparing solutions,
suspensions, emulsions, syrups and elixirs. The active ingredient of this invention
10 can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as
water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
The liquid carrier can contain other suitable pharmaceutical additives such as
solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents,
suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-
15 regulators. Suitable examples of liquid carriers for oral and parenteral administration
include water (particularly containing additives as above, e.g., cellulose derivatives,
preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric
alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g.,
fractionated coconut oil and arachis oil). For parenteral administration, the carrier
20 can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid
carriers are used in sterile liquid form compositions for parenteral administration.
Liquid pharmaceutical compositions, which are sterile solutions or suspensions can
be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection.
Sterile solutions can also be administered intravenously. Oral administration may be
25 either in liquid or solid composition form. Preferably, the pharmaceutical
compositions containing the present compounds are in unit dosage form, e.g., as
tablets or capsules. In such form, the composition is sub-divided in unit dosages
containing appropriate quantities of the active ingredients. The unit dosage forms can
be packaged compositions, for example, packaged powders, vials, ampoules, prefilled
syringes or sachets containing liquids. Alternatively, the unit dosage form can be, for
30 example, a capsule or tablet itself, or it can be the appropriate number of any such
compositions in package form. The therapeutically effective dosage to be used in the
treatment of a specific disease or condition must be subjectively determined by the
attending physician. The variables involved include the specific condition(s) being
treated and the size, age and response pattern of the patient.

35


The present invention may be embodied in other specific forms without
departing from the spirit and essential attributes thereof and accordingly, reference

[illegible]

5

What is Claimed:

1. A compound of the formula (I):



10

wherein:

X is selected from $-\text{CH}_2-$ or a chemical bond;

Y is selected from $-(\text{CH}_2)_m-$ or $-(\text{CH}_2)-\text{O}-(\text{CH}_2)-$;

m is selected from the integer 0 or 1;

15

n is selected from the integer 0 or 1;

R_1 and R_2 are independently selected from the group consisting of aryl or

heteroaryl of from 5 – 10 atoms optionally substituted with F, Cl, Br, I, $-\text{OH}$, $-\text{NH}_2$, $-\text{CO}_2\text{H}$, $-\text{CO}_2-\text{C}_1-\text{C}_6$ alkyl, $-\text{CN}$, $-\text{NO}_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 perhaloalkyl, OR_3 , or C_1-C_6 perhaloalkoxy;


20

R_3 is selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_6-C_{10} aryl, mono or bicyclic heteroaryl, C_7-C_{14} aralkyl, and mono or bicyclic heteroaralkyl, where the aryl or heteroaryl group is optionally substituted with one to three substituents independently selected from the group consisting of F, Cl, Br, I, CN, $-\text{NH}_2$, $-\text{NO}_2$, $-\text{OH}$, alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 perhaloalkyl, C_1-C_6 alkoxy, and C_1-C_6 perhaloalkoxy; and the optical isomers or a pharmaceutically acceptable salt thereof.

25

2. A compound of Claim 1 having the formula:

- 24 -



5

wherein:

Y is selected from $-(CH_2)_m-$ or $-(CH_2)_m-O-(CH_2)_m-$;


m is selected from the integer 0 or 1;

10 n is selected from the integer 0 or 1;

R_1 is phenyl optionally substituted with F, Cl, Br, I, -OH, -NH₂, -CO₂H, -CO₂-C₁-C₆ alkyl, -CN, -NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perhaloalkyl or C₁-C₆ perhaloalkoxy;

15 R_2 is selected from phenyl, naphthyl, piperazinyl, pyridine, thiophene, furan, imidazole, oxazole, pyrrole, pyrimidine, pyridazine, pyrazine, thiazole or oxathiazole; and the optical isomers or a pharmaceutically acceptable salt thereof.

3. A compound of Claim 1 of the formula:



20

wherein:

Y is selected from $-CH_2-$;

m is selected from the integer 0 or 1;

n is selected from the integer 0 or 1;

25 R_1 is phenyl optionally substituted with F, Cl, Br, I, -OH, -NH₂, -CO₂H, -CO₂-C₁-C₆ alkyl, -CN, -NO₂, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perhaloalkyl or C₁-C₆ perhaloalkoxy;

R_2 is phenyl or pyrimidinyl;

- 25 -

5 and the optical isomers or a pharmaceutically acceptable salt thereof.

4. A compound of Claim 1 which is (R)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate.

10

5. A compound of Claim 1 which is (R)-Phenylalanine-N-[4-(phenylmethyl)-1-piperizinyl]carboxamide Dihydrochloride.

15

6. A compound of Claim 1 which is (R)-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]amine.

20

7. A compound of Claim 1 which is (R)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo-[3.3.1.^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate.

8. A compound of Claim 1 which is (S)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate.

25

9. A compound of Claim 1 which is (R)-N-[1-(Phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.^{3,7}]-decane-1-carboxamide Hemihydrate

30

10. A compound of Claim 1 which is (S)-N-[1-(Phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.^{3,7}]-decane-1-carboxamide

11. A compound of Claim 1 which is (R)-N-[1-((Phenylmethoxy)methyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo-[3.3.1.^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate

35

12. A compound of Claim 1 which is (R)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hemihydrate.

- 26 -

5

13. A compound of Claim 1 which is (R)-[1-(Phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxo-ethyl]-carbamic acid tert-butyl ester.

10 14. A compound of Claim 1 which is (R)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hemihydrate.

15 15. A compound of Claim 1 which is (S)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hydrate.

20 16. A method for treating neurodegenerative disorders comprising administering a therapeutically effective amount of a compound of Claim 1 or a pharmaceutical salt thereof, to a patient in need of said treatment.

17. The method of Claim 16 wherein the neurodegenerative disorder is chronic.

25 18. The method of Claim 16 wherein the neurodegenerative disorder is Alzheimer's Disease.

19. The method of Claim 16 wherein the neurodegenerative disorder is Huntington's Disease.

30 20. The method of Claim 16 wherein the neurodegenerative disorder is Parkinson's Disease.

21. The method of Claim 16 wherein the neurodegenerative disorder is AIDS dementia.

35

- 27 -

5 22. The method of Claim 16 wherein the neurodegenerative disorder is
retinal disease.

 23. The method of Claim 16 wherein the neurodegenerative disorder is
epilepsy.

10

 24. The method of Claim 16 wherein the neurodegenerative disorder is
amyotrophic lateral sclerosis.

15

 25. The method of Claim 16 wherein the neurodegenerative disorder is
acute.

 26. The method of claim 25 wherein the neurodegenerative disorder is
stroke.

20

 27. The method of claim 26 wherein stroke is acute thromboembolic
stroke.

 28. The method of claim 26 wherein stroke is focal ischemia.

25

 29. The method of claim 26 wherein stroke is global ischemia.

 30. The method of claim 26 wherein stroke is transient ischemic attack.

30 31. The method of Claim 16 wherein the neurodegenerative disorder is
ischemia resulting from a surgical technique involving prolonged halt of blood flow
to the brain.

 32. The method of claim 16 wherein the neurodegenerative disorder is
head trauma.

- 28 -

5

33. The method of claim 16 wherein the neurodegenerative disorder is spinal trauma.

34. The method of claim 16 wherein the neurodegenerative disorder is
10 hypoxia.

35. The method of claim 34 wherein the hypoxia is fetal hypoxia.

36. A method of neuroprotection comprising administering a
15 therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

37. A method of treating chronic pain comprising administering a
therapeutically effective amount of a compound of Claim 1 or a pharmaceutical salt
20 thereof, to a patient in need of said treatment.

38. The method of Claim 37 wherein the chronic pain is diabetic peripheral neuropathy.


25

- 29 -

5

ABSTRACT OF THE DISCLOSURE

This invention provides compounds and methods using them to provide neuroprotection and prevent or limit processes of neurodegeneration in mammals, including Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, AIDS dementia, retinal disease, diabetic peripheral neuropathy, multiple sclerosis, stroke, acute thromboembolic stroke, focal ischemia, global ischemia, transient ischemic attack, ischemia resulting from surgery, head trauma, spinal trauma, hypoxia, fetal hypoxia, and neuroprotection., the compounds having the structure:



15

wherein X is -CH₂- or a bond; Y is -(CH₂)_m- or -(CH₂)-O-(CH₂)-; m 0 or 1; n is 0 or 1; R₁ and R₂ are independently selected from optionally substituted aryl or heteroaryl; the optical isomers and the pharmaceutically acceptable salts thereof.

DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Branched Adamantyl and Noradamantyl Aryl- and Aralkylpiperazines with Serotonin 5-HT1A Activity, the specification of which

(check one) _____ is attached hereto.

_____ was filed on _____ as
Application Serial No. _____
and was amended on _____.
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority Claimed
Yes No

(Number) (Country) (Day/Month/Year Filed)

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States Provisional Application(s) for Patent listed below:

60/228,820 November 12, 1999 which was converted from U.S. Patent Application
(Provisional Appln. No.) (Filing Date) No. 09/439,798, filed November 12, 1999, pursuant
to a petition filed under 37 C.F.R. 1.53(c)(2)(i).

Not Yet Known November 18, 1999 which was converted from U.S. Patent Application
(Provisional Appln. No.) (Filing Date) No. 09/442,981, filed November 18, 1999, pursuant
to a petition filed under 37 C.F.R. 1.53(c)(2)(i).

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Pending

(Application Serial No.) (Filing Date) (Status - Patented, pending, abandoned)

(Application Serial No.) (Filing Date) (Status - Patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Egon E. Berg, Reg. No. 21,117, of One Campus Drive, Parsippany, New Jersey, 07054; and Rebecca R. Barrett, Reg. No. 35,152; Steven R. Eck, Reg. No. 36,126; Arnold S. Milowsky, Reg. No. 35,288; Michael R. Nagy, Reg. No. 33,432; George Tarnowski, Reg. No. 27,472; all of P.O. Box 8299, Philadelphia, Pennsylvania, 19101; Daniel B. Moran, Reg. No. 41,204 of 401 N. Middletown Road, Pearl River, New York, 10965; and Barbara L. Lences, Reg. No. 41,148, of CN-8000, Princeton, New Jersey, 08543-8000.

Address all telephone calls to Steven R. Eck at telephone number (610) 902-2628.

Address all correspondence to Egon E. Berg, American Home Products Corporation, Patent Law Department - 2B, One Campus Drive, Parsippany, New Jersey, 07054.

Full name of sole or first inventor Wayne E. Childers, Jr.

Inventor's signature Wayne E. Childers, Jr. 10/27/00
Date

Residence 201 Riverwood Drive, New Hope, Pennsylvania, 18938

Citizenship United States of America

Post Office Address Same as residence

Full name of second joint inventor, if any Horace Fletcher, III

Inventor's signature Horace Fletcher, III 11/6/00
Date

Residence 2382 Schaffer Road, Pottstown, Pennsylvania, 19464

Citizenship United States of America

Post Office Address Same as residence

Full name of third joint inventor, if any Magid A. Abou-Gharbia

Inventor's signature *Magid A. Abou-Gharbia* 10/27/00
Date

Residence 26 Hawthorne Drive, Princeton Junction, New Jersey, 08550

Citizenship United States of America

Post Office Address Same as residence

Full name of fourth joint inventor, if any John P. Yardley

Inventor's signature *John P. Yardley* 10/06/00
Date

Residence 154 Hughes Road, King of Prussia, Pennsylvania, 19406

Citizenship United States of America

Post Office Address Same as residence